Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 696 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatitis, Chronic Clear all

Conditions: Chronic Hepatitis B
Interventions: TAF, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 15
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 12 more

Conditions: Hepatitis B Virus
Interventions: pegIFN, pegIFNα-2a, PegIFN lambda, Entecavir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 13
States / cities: Anaheim, California • Garden Grove, California • Sacramento, California + 9 more

Conditions: Hepatitis C
Interventions: Single Ascending Dose Cohorts GS-9620, Multiple Ascending Dose Cohorts GS-9620; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 10
States / cities: Little Rock, Arkansas • DeLand, Florida • Orlando, Florida + 7 more

Conditions: Chronic Hepatitis B
Interventions: NCO-48 Fumarate 4 mg, NCO-48 Fumarate 20 mg, Tenofovir Alafenamide 25 mg; Drug
Lead sponsor: Nucorion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Monterey Park, California

Conditions: Hepatitis C
Interventions: Daclatasvir, Telaprevir, Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 19 more

Conditions: Hepatitis B, Chronic
Interventions: VIR-2218, VIR-3434, PEG-IFNα; Drug
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 5
States / cities: San Francisco, California • Miami, Florida • Orlando, Florida + 2 more

Conditions: Hepatitis B, Chronic Disease
Interventions: entecavir, adefovir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 16 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 11
States / cities: San Diego, California • San Francisco, California • Torrance, California + 7 more

Conditions: Hepatitis C Virus Infection
Interventions: Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 99 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 8
States / cities: Dothan, Alabama • Los Angeles, California • Baltimore, Maryland + 5 more

Conditions: Autoimmune Hepatitis
Interventions: Dietary assignment; Dietary Supplement
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hepatitis C, Chronic
Interventions: Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 12
States / cities: Birmingham, Alabama • Kansas City, Kansas • New Orleans, Louisiana + 9 more

Conditions: Chronic Hepatitis B
Interventions: telbivudine or lamivudine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 16 Years to 70 Years
Timeline: Started 2003
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • San Diego, California + 2 more

Conditions: Hepatitis C
Interventions: Locteron (controlled-release interferon alpha 2b), pegylated IFNa2b; Other · Biological
Lead sponsor: Biolex Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 5
States / cities: Detroit, Michigan • Dallas, Texas • San Antonio, Texas + 2 more

Conditions: Hepatitis C Virus
Interventions: Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 7
States / cities: Bakersfield, California • Jacksonville, Florida • Lutherville, Maryland + 4 more

Conditions: Hepatitis B
Interventions: Tenofovir Alafenamide; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Autoimmune Hepatitis
Interventions: LCP-Tacro (tacrolimus), Azathioprine; Drug
Lead sponsor: Asahi Kasei Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 8
States / cities: Phoenix, Arizona • Jacksonville, Florida • Chicago, Illinois + 5 more

Conditions: HCV Infection
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 39
States / cities: Beverly Hills, California • La Jolla, California • Los Angeles, California + 34 more

Conditions: Chronic Hepatitis C
Interventions: Viramidine, Ribavirin, pegylated interferon alfa-2a; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 53
States / cities: Tucson, Arizona • Fresno, California • Los Angeles, California + 42 more

Conditions: Chronic Genotype 1 Hepatitis C Virus Infection
Interventions: PPI-461, Placebo; Drug
Lead sponsor: Presidio Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Sacramento, California • San Francisco, California

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL/VOX, SOF/VEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 43
States / cities: Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more

Conditions: Hepatitis C
Interventions: BMS-790052 (NS5A Replication Complex Inhibitor), Placebo matching BMS-790052, Pegylated-interferon alfa 2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 4
States / cities: San Clemente, California • Worcester, Massachusetts • Providence, Rhode Island + 1 more

Conditions: Chronic Hepatitis C
Interventions: Not listed
Lead sponsor: Avera McKennan Hospital & University Health Center; Other
Eligibility: 20 Years to 60 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Hepatitis C, Cirrhosis
Interventions: daclatasvir, Sofosbuvir, Sovaldi, Ribavirin; Drug
Lead sponsor: Tarek I. Hassanein, M.D., FACP, FAG, AGAF; Other
Eligibility: 18 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Coronado, California

Conditions: Sequelae of; Infection, Post Infection Glomerulonephritis, Post-Infectious Peripheral Neuralgia, Post-Infectious Disorder (Disorder), Post-Infectious Arthritis, Post-Infectious Polyneuritis, Post-Infectious Parkinsonism, Post-Infectious Hypothyroidism, Post Infectious Osteoarthritis, Anxiety Disorders, Depression, Depression, Anxiety, Depression, Bipolar, Insomnia, GERD, Gastro Esophageal Reflux, Hepatitis, Glomerulonephritis
Interventions: PurWet, FurFat, PurApo, PurPhl, PurClo, PurInf, Smoliv; Combination Product
Lead sponsor: All Natural Medicine Clinic, LLC; Other
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Hepatitis C
Interventions: Daclatasvir, Sofosbuvir, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Miami, Florida • Ann Arbor, Michigan • Houston, Texas + 2 more

Search by objective public record fields.

Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection

Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C

Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B

Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study

Mediterranean Diet Versus Western Diet on Fatigue in Autoimmune Hepatitis Patients

A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment

A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B

Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C

Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

Entecavir to TAF Switch

LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis

Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive

A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor

Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

Vitamin D Deficiency in Subjects With Chronic Hepatitis C Compared to Healthy Volunteers

Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics

Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2

Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant